Zynex Inc. (OTCMKTS:ZYXI) released its quarterly earnings results on Monday. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01, Bloomberg Earnings reports. Zynex had a negative return on equity of 86.24% and a net margin of 18.12%.

Zynex (ZYXI) opened at $3.00 on Tuesday. Zynex has a 12 month low of $0.10 and a 12 month high of $2.94. The stock has a market capitalization of $91.66, a PE ratio of 35.75 and a beta of -0.03. The company has a quick ratio of 0.60, a current ratio of 0.64 and a debt-to-equity ratio of -0.04.

A number of equities research analysts have commented on ZYXI shares. Taglich Brothers reiterated a “speculative buy” rating on shares of Zynex in a research note on Monday, August 21st. ValuEngine upgraded Zynex from a “hold” rating to a “buy” rating in a research note on Wednesday, August 23rd.

TRADEMARK VIOLATION WARNING: “Zynex Inc. (ZYXI) Issues Earnings Results” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.watchlistnews.com/zynex-inc-zyxi-issues-earnings-results/1702253.html.

About Zynex

Zynex, Inc operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation.

Earnings History for Zynex (OTCMKTS:ZYXI)

Receive News & Ratings for Zynex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.